Our lead product for severe pneumonia, plasma gelsolin, has application for COVID19.

Richard G. Wunderink, MD

Richard Wunderink, MD, is a professor of medicine in the Pulmonary and Critical Care Division of Northwestern University’s Feinberg School of Medicine and medical director of the MICU, Northwestern Memorial Hospital. His research and education focus includes pulmonary infections, especially ventilator-associated pneumonia and community-acquired pneumonia and sepsis. He served as co-chairman of the most recent IDSA/ATS Consensus Guidelines Committee on the management of community-acquired pneumonia.  Dr. Wunderink has been active in research and education regarding pulmonary infections, especially ventilator-associated pneumonia and community-acquired pneumonia, and sepsis. He is a member of the last two committees of the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), which developed guideline statements on hospital-acquired and healthcare-associated pneumonia. He co-chaired the most recent IDSA/ATS Consensus Guidelines Committee on the management of community-acquired pneumonia. He has a grant from the CDC to study the incidence and etiology of community-acquired pneumonia in hospitalized patients and from the NIAID for ventilator-associated pneumonia treatment.